Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease

• Main Authors: Hu Li (Author), Nan-Nan Liu (Author), Jian-Rui Li (Author), Biao Dong (Author), Mei-Xi Wang (Author), Jia-Li Tan (Author), Xue-Kai Wang (Author), Jing Jiang (Author), Lei Lei (Author), Hong-Ying Li (Author), Han Sun (Author), Jian-Dong Jiang (Author), Zong-Gen Peng (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Nonalcoholic fatty liver disease (NAFLD), ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), is a liver disease worldwide without approved therapeutic drugs. Anti-inflammatory and hepatoprotective drug bicyclol and multi-pharmacological active drug berberine, respectively, have sh...